Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues

Leukemia

Volumn 28, Issue 5, 2014, Pages 1167-1170

  Goswami, M ^a   Hensel, N ^a   Smith, B D ^b   Prince, G T ^b   Qin, L ^b   Levitsky, H I ^b,c   Strickland, S A ^d   Jagasia, M ^d   Savani, B N ^d   Fraser, J W ^e   Sadrzadeh, H ^e   Rajkhowa, T ^b   Ito, S ^b   Jain, N A ^a   Battiwalla, M ^a   Fathi, A T ^e   Levis, M J ^b   Barrett, A J ^a   Hourigan, C S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Roche Glycart   (Switzerland)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LEUKEMIA ANTIGEN; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA ISOLATION; ERYTHROLEUKEMIA CELL; FLOW CYTOMETRY; GENE EXPRESSION; GLOBIN GENE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION;

HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE;

EID: 84899949862     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.14     Document Type: Letter

References (15)

1. Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR. et al. Generation of multi-leukemia antigen-specific T cells to enhance the graftversus-leukemia effect after allogeneic stem cell transplant. Leukemia 2013; 27: 1538-1547.
2. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-Associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26: 2186-2196.
3. el-Shami K, Smith BD. Immunotherapy for myeloid leukemias: Current status and future directions. Leukemia 2008; 22: 1658-1664.
4. Greiner J, Bullinger L, Guinn B-A, Doehner H, Schmitt M. Leukemia-Associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008; 14: 7161-7166.
5. Hourigan CS, Levitsky HI. Evaluation of current cancer immunotherapy: Hematooncology. Cancer J 2011; 17: 309-324.
6. Guinn BA, Gilkes AF, Woodward E, Westwood NB, Mufti GJ, Linch D. et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 333: 703-713.
7. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y. et al. Cancer-Testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 2011; 86: 918-922.
8. Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR. et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-Testis antigen. Blood 2012; 119: 5492-5501.
9. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT. et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.
10. Schmittgen TD, Livak KJ. Analyzing real-Time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
11. Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M. et al. Induction of high-Titer IgG antibodies against multiple leukemia-Associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer J 2013; 3: E145.
12. Brackertz B, Conrad H, Daniel J, Kast B, Kronig H, Busch DH. et al. FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. Blood Cancer J 2011; 1: E11.
13. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A. et al. Expression of tumor-Associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
14. Greiner J, Schneider V, Schmitt M, Goötz M, Doöhner K, Wiesneth M. et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 2013; 122: 1087-1088.
15. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013; 10: 460-471.